48 related articles for article (PubMed ID: 32006630)
1. Serum-free production of rVSV-ZEBOV in Vero cells: Microcarrier bioreactor versus scale-X™ hydro fixed-bed.
Kiesslich S; Vila-Chã Losa JP; Gélinas JF; Kamen AA
J Biotechnol; 2020 Feb; 310():32-39. PubMed ID: 32006630
[TBL] [Abstract][Full Text] [Related]
2. Development of an HSV-1 production process involving serum-reduced culturing and bead-to-bead transfer.
Wang H; Hu X; Zhang M; Yang L; Xu Y; Gu X; Jiang J; Hu W
Appl Microbiol Biotechnol; 2024 Jun; 108(1):383. PubMed ID: 38896301
[TBL] [Abstract][Full Text] [Related]
3. Real-Time Capture and Visualization of Individual Viruses in Complex Media.
Scherr SM; Daaboul GG; Trueb J; Sevenler D; Fawcett H; Goldberg B; Connor JH; Ünlü MS
ACS Nano; 2016 Feb; 10(2):2827-33. PubMed ID: 26760677
[TBL] [Abstract][Full Text] [Related]
4. Flow virometry for process monitoring of live virus vaccines-lessons learned from ERVEBO.
Ricci G; Minsker K; Kapish A; Osborn J; Ha S; Davide J; Califano JP; Sehlin D; Rustandi RR; Dick LW; Vlasak J; Culp TD; Baudy A; Bell E; Mukherjee M
Sci Rep; 2021 Apr; 11(1):7432. PubMed ID: 33795759
[TBL] [Abstract][Full Text] [Related]
5. Vero cell upstream bioprocess development for the production of viral vectors and vaccines.
Kiesslich S; Kamen AA
Biotechnol Adv; 2020 Nov; 44():107608. PubMed ID: 32768520
[TBL] [Abstract][Full Text] [Related]
6. Benchmarking of Scale-X Bioreactor System in Lentiviral and Adenoviral Vector Production.
Leinonen HM; Lepola S; Lipponen EM; Heikura T; Koponen T; Parker N; Ylä-Herttuala S; Lesch HP
Hum Gene Ther; 2020 Mar; 31(5-6):376-384. PubMed ID: 32075423
[TBL] [Abstract][Full Text] [Related]
7. Enhanced production yields of rVSV-SARS-CoV-2 vaccine using Fibra-Cel
Cohen N; Simon I; Hazan O; Tal A; Tzadok H; Levin L; Girshengorn M; Mimran LC; Natan N; Baruhi T; David AB; Rosen O; Shmaya S; Borni S; Cohen N; Lupu E; Kedmi A; Zilberman O; Jayson A; Monash A; Dor E; Diamant E; Goldvaser M; Cohen-Gihon I; Israeli O; Lazar S; Shifman O; Beth-Din A; Zvi A; Oren Z; Makovitzki A; Lerer E; Mimran A; Toister E; Zichel R; Adar Y; Epstein E
Front Bioeng Biotechnol; 2024; 12():1333548. PubMed ID: 38449674
[TBL] [Abstract][Full Text] [Related]
8. High-titer manufacturing of SARS-CoV-2 Spike-pseudotyped VSV in stirred-tank bioreactors.
Todesco HM; Gafuik C; John CM; Roberts EL; Borys BS; Pawluk A; Kallos MS; Potts KG; Mahoney DJ
Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101189. PubMed ID: 38327804
[TBL] [Abstract][Full Text] [Related]
9. Development of an Integrated Continuous Manufacturing Process for the rVSV-Vectored SARS-CoV-2 Candidate Vaccine.
Yang Z; Paes BCMF; Fulber JPC; Tran MY; Farnós O; Kamen AA
Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112753
[TBL] [Abstract][Full Text] [Related]
10. Development and scale-up of rVSV-SARS-CoV-2 vaccine process using single use bioreactor.
Ton C; Stabile V; Carey E; Maraikar A; Whitmer T; Marrone S; Afanador NL; Zabrodin I; Manomohan G; Whiteman M; Hofmann C
Biotechnol Rep (Amst); 2023 Mar; 37():e00782. PubMed ID: 36687766
[TBL] [Abstract][Full Text] [Related]
11. Application of bioreactor technology for cell culture-based viral vaccine production: Present status and future prospects.
Fang Z; Lyu J; Li J; Li C; Zhang Y; Guo Y; Wang Y; Zhang Y; Chen K
Front Bioeng Biotechnol; 2022; 10():921755. PubMed ID: 36017347
[TBL] [Abstract][Full Text] [Related]
12. From functional genomics of vero cells to CRISPR-based genomic deletion for improved viral production rates.
Sène MA; Xia Y; Kamen AA
Biotechnol Bioeng; 2022 Oct; 119(10):2794-2805. PubMed ID: 35869699
[TBL] [Abstract][Full Text] [Related]
13. Cell-line screening and process development for a fusogenic oncolytic virus in small-scale suspension cultures.
Göbel S; Kortum F; Chavez KJ; Jordan I; Sandig V; Reichl U; Altomonte J; Genzel Y
Appl Microbiol Biotechnol; 2022 Aug; 106(13-16):4945-4961. PubMed ID: 35767011
[TBL] [Abstract][Full Text] [Related]
14. Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use.
Fulber JPC; Kamen AA
Viruses; 2022 May; 14(5):. PubMed ID: 35632717
[TBL] [Abstract][Full Text] [Related]
15. Optimization of VSV-ΔG-spike production process with the Ambr15 system for a SARS-COV-2 vaccine.
Rosen O; Jayson A; Goldvaser M; Dor E; Monash A; Levin L; Cherry L; Lupu E; Natan N; Girshengorn M; Epstein E
Biotechnol Bioeng; 2022 Jul; 119(7):1839-1848. PubMed ID: 35319097
[TBL] [Abstract][Full Text] [Related]
16. A Review of the Use of Microparticles for Cartilage Tissue Engineering.
Kulchar RJ; Denzer BR; Chavre BM; Takegami M; Patterson J
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638629
[TBL] [Abstract][Full Text] [Related]
17. Establishment of
Álvarez Martínez JA; Figueroa Millán JV; Ueti MW; Rojas-Martínez C
Pathogens; 2021 Jun; 10(6):. PubMed ID: 34205286
[No Abstract] [Full Text] [Related]
18. Bioreactor production of rVSV-based vectors in Vero cell suspension cultures.
Kiesslich S; Kim GN; Shen CF; Kang CY; Kamen AA
Biotechnol Bioeng; 2021 Jul; 118(7):2649-2659. PubMed ID: 33837958
[TBL] [Abstract][Full Text] [Related]
19. Investigating the Interaction between Negative Strand RNA Viruses and Their Hosts for Enhanced Vaccine Development and Production.
Mara K; Dai M; Brice AM; Alexander MR; Tribolet L; Layton DS; Bean AGD
Vaccines (Basel); 2021 Jan; 9(1):. PubMed ID: 33477334
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis.
Bayati A; Kumar R; Francis V; McPherson PS
J Biol Chem; 2021; 296():100306. PubMed ID: 33476648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
